PRLD
Prelude Therapeutics Incorporated
NASDAQ · Healthcare · Biotechnology · US
$5.46
+4.00%Margins
Gross margin
98.3%
EBITDA margin
-262.7%
EBIT margin
-300.6%
Net margin
-269.7%
FCF margin
-148.3%
-45.2%
Return on equity
-31.9%
Return on assets
-44.5%
Return on invested capital
0.15x
Asset turnover
-$33.3M
Cash from operations
$1.90
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026